All In Biotech

Drug Trial Radar · NCT04974398

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

A Randomized, Double-blind, Multi-center Phase III Study of Penpulimab (AK105) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Last checked: Nov 19, 2026Latest source record: Apr 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 296 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

296

Actual

Start

Aug 16, 2021

Primary completion

Feb 23, 2026

Study completion Dec 23, 2026

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Jul 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

  • PenpulimabDrug

    Arm A: Penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) +cisplatin (80 mg/m2) or carboplatin (AUC 5) (administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/ m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), 3 weeks (21 days) per cycle; followed by penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) as maintenance treatment.

  • placeboDrug

    Arm B: Placebo (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin (80 mg/m2) or carboplatin (AUC 5) (administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), every 3 weeks (21 days) per cycle; followed by placebo(200 mg, administered on Day 1 of each cycle, Q3W) as maintenance treatment. Subjects in Arm B will have the opportunity to crossover to openlabel treatment with penpulimab monotherapy after radiographic disease progression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Up to 2 years

Locations

56 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • Winship Cancer Institute/Emory University

    Atlanta, Georgia

  • University of Michigan

    Ann Arbor, Michigan

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia

  • St Vincent's Public Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Genesis Care North Shore

    St Leonards, New South Wales, Australia

  • Sir Charles Gardner

    Heidelberg, Victoria, Australia

  • Austin Health

    Nedlands, Western Australia, Australia

  • Hospital de Câncer de Barretos - Fundação Pio XII

    Barretos, REG1, Brazil

  • Grupo Oncoclínicas

    Botafogo, REG1, Brazil

  • Hospital Bruno Born

    Lajeado, REG1, Brazil

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, REG1, Brazil

  • Centro de Estudos e Pesquisa de Hematologia

    Santo André, REG1, Brazil

  • Instituto do Câncer do Estado de São Paulo (ICESP)

    São Paulo, REG1, Brazil

  • Centro de Câncer A. C. Camargo

    São Paulo, REG1, Brazil

  • Alberta Health Services (Tom Baker Cancer Centre)

    Calgary, Alberta, Canada

  • Toronto Sunnybrook Hospital

    Toronto, Ontario, Canada

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Dongguan People's Hospital

    Dongguan, Guangdong, China

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China

  • The Sixth Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Guangdong Pharmaceutical University

    Guangzhou, Guangdong, China

  • Guangzhou Panyu Central Hospital

    Guangzhou, Guangdong, China

  • Jiangmen Central Hospital

    Jiangmen, Guangdong, China

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China

  • The Fifth Affiliated Hospital of Sun Yat-sen University

    Zhuhai, Guangdong, China

  • Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.